

Melissa L Fishel

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/6910716/publications.pdf>

Version: 2024-02-01

86
papers

4,034
citations

126708

33
h-index

123241

61
g-index

91
all docs

91
docs citations

91
times ranked

5179
citing authors

#	ARTICLE	IF	CITATIONS
1	Inhibition of PRMT5 by market drugs as a novel cancer therapeutic avenue. <i>Genes and Diseases</i> , 2023, 10, 267-283.	1.5	4
2	Hypoxia signaling: Challenges and opportunities for cancer therapy. <i>Seminars in Cancer Biology</i> , 2022, 85, 185-195.	4.3	17
3	RelA Is an Essential Target for Enhancing Cellular Responses to the DNA Repair/Ref-1 Redox Signaling Protein and Restoring Perturbed Cellular Redox Homeostasis in Mouse PDAC Cells. <i>Frontiers in Oncology</i> , 2022, 12, 826617.	1.3	5
4	Refining colorectal cancer classification and clinical stratification through a single-cell atlas. <i>Genome Biology</i> , 2022, 23, 113.	3.8	48
5	Abstract 2366: Inhibition of Ref-1/APE1 redox activity with APX3330 enhances Ref-1/APE1 protein unfolded conformation in human PDAC cells. <i>Cancer Research</i> , 2022, 82, 2366-2366.	0.4	0
6	The multifunctional APE1 DNA repair/redox signaling protein as a drug target in human disease. <i>Drug Discovery Today</i> , 2021, 26, 218-228.	3.2	61
7	Combined inhibition of Ref-1 and STAT3 leads to synergistic tumour inhibition in multiple cancers using 3D and in vivo tumour culture models. <i>Journal of Cellular and Molecular Medicine</i> , 2021, 25, 784-800.	1.6	9
8	Exploring transcriptional regulators Ref-1 and STAT3 as therapeutic targets in malignant peripheral nerve sheath tumours. <i>British Journal of Cancer</i> , 2021, 124, 1566-1580.	2.9	12
9	A graph neural network model to estimate cell-wise metabolic flux using single-cell RNA-seq data. <i>Genome Research</i> , 2021, 31, 1867-1884.	2.4	60
10	Abstract 2475: Differential sensitivity of mouse PDAC KrasG12D cells to Ref-1/APE1 redox signalling inhibitors: Role of NFκB as a primary target of Ref-1/APE1 in Kras driven pancreatic ductal adenocarcinoma. , 2021, , .		0
11	Abstract 1088: Advancing non-cytotoxic DNMT1-targeting to treat chemorefractory pancreatic cancer. , 2021, , .		0
12	Ref-1 redox activity alters cancer cell metabolism in pancreatic cancer: exploiting this novel finding as a potential target. <i>Journal of Experimental and Clinical Cancer Research</i> , 2021, 40, 251.	3.5	23
13	Biomimetic stiffening of cell-laden hydrogels via sequential thiol-ene and hydrazone click reactions. <i>Acta Biomaterialia</i> , 2021, 130, 161-171.	4.1	13
14	Clinical and Preclinical Outcomes of Combining Targeted Therapy With Radiotherapy. <i>Frontiers in Oncology</i> , 2021, 11, 749496.	1.3	13
15	APE1/Ref-1 - One Target with Multiple Indications: Emerging Aspects and New Directions. <i>Journal of Cellular Signaling</i> , 2021, 2, 151-161.	0.5	3
16	Pharmacological inhibition of Carbonic Anhydrase IX and XII to enhance targeting of acute myeloid leukaemia cells under hypoxic conditions. <i>Journal of Cellular and Molecular Medicine</i> , 2021, 25, 11039-11052.	1.6	7
17	Regulation of cellular sterol homeostasis by the oxygen responsive noncoding RNA lincNORS. <i>Nature Communications</i> , 2020, 11, 4755.	5.8	12
18	Phenotypic Screening of Chemical Libraries Enriched by Molecular Docking to Multiple Targets Selected from Glioblastoma Genomic Data. <i>ACS Chemical Biology</i> , 2020, 15, 1424-1444.	1.6	4

#	ARTICLE	IF	CITATIONS
19	Long-Term Gemcitabine Treatment Reshapes the Pancreatic Tumor Microenvironment and Sensitizes Murine Carcinoma to Combination Immunotherapy. <i>Cancer Research</i> , 2020, 80, 3101-3115.	0.4	77
20	LTMG: a novel statistical modeling of transcriptional expression states in single-cell RNA-Seq data. <i>Nucleic Acids Research</i> , 2019, 47, e1111-e1111.	6.5	46
21	Identification and Characterization of AES-135, a Hydroxamic Acid-Based HDAC Inhibitor That Prolongs Survival in an Orthotopic Mouse Model of Pancreatic Cancer. <i>Journal of Medicinal Chemistry</i> , 2019, 62, 2651-2665.	2.9	28
22	Antitumor Activity and Mechanistic Characterization of APE1/Ref-1 Inhibitors in Bladder Cancer. <i>Molecular Cancer Therapeutics</i> , 2019, 18, 1947-1960.	1.9	29
23	Abstract C017: Signaling through Ref-1 and STAT3 in soft tissue sarcoma (MPNST) and the effects of perturbing this pathway on tumor cell survival and gene expression. , 2019, , .		0
24	PTEN-Dependent Stabilization of MTSS1 Inhibits Metastatic Phenotype in Pancreatic Ductal Adenocarcinoma. <i>Neoplasia</i> , 2018, 20, 12-24.	2.3	14
25	APE1/Ref-1 redox-specific inhibition decreases survivin protein levels and induces cell cycle arrest in prostate cancer cells. <i>Oncotarget</i> , 2018, 9, 10962-10977.	0.8	29
26	Blocking HIF signaling via novel inhibitors of CA9 and APE1/Ref-1 dramatically affects pancreatic cancer cell survival. <i>Scientific Reports</i> , 2018, 8, 13759.	1.6	37
27	Development of a Novel 3D Tumor-tissue Invasion Model for High-throughput, High-content Phenotypic Drug Screening. <i>Scientific Reports</i> , 2018, 8, 13039.	1.6	56
28	Ref-1/APE1 Inhibition with Novel Small Molecules Blocks Ocular Neovascularization. <i>Journal of Pharmacology and Experimental Therapeutics</i> , 2018, 367, 108-118.	1.3	33
29	Presence of stromal cells in a bioengineered tumor microenvironment alters glioblastoma migration and response to STAT3 inhibition. <i>PLoS ONE</i> , 2018, 13, e0194183.	1.1	31
30	Targeting Ocular Neovascularization with Novel APE1/Ref-1 Inhibitors. <i>FASEB Journal</i> , 2018, 32, .	0.2	0
31	Abstract 2941: APE1/Ref-1 redox signaling regulates HIF1a-mediated CA9 expression in hypoxic pancreatic cancer cells: Combination treatment in patient-derived pancreatic tumor models. , 2018, , .		0
32	Abstract 4802: Combination therapy in PDAC involving blockade of the APE1/Ref-1 signaling pathway: An investigation into drug synthetic lethality and anti-neuropathy therapeutic approach. , 2018, , .		0
33	Ref-1/APE1 as a Transcriptional Regulator and Novel Therapeutic Target in Pediatric T-cell Leukemia. <i>Molecular Cancer Therapeutics</i> , 2017, 16, 1401-1411.	1.9	17
34	APE1 knockdown in pancreatic ductal adenocarcinoma "characterizing gene expression changes and identifying novel pathways using single-cell RNA sequencing. <i>Molecular Oncology</i> , 2017, 11, 1711-1732.	2.1	27
35	Exploiting the Ref-1-APE1 node in cancer signaling and other diseases: from bench to clinic. <i>Npj Precision Oncology</i> , 2017, 1, .	2.3	97
36	Cancer-associated fibroblast exosomes regulate survival and proliferation of pancreatic cancer cells. <i>Oncogene</i> , 2017, 36, 1770-1778.	2.6	553

#	ARTICLE	IF	CITATIONS
37	Loss of MTSS1 results in increased metastatic potential in pancreatic cancer. <i>Oncotarget</i> , 2017, 8, 16473-16487.	0.8	15
38	Adapting AlphaLISA high throughput screen to discover a novel small-molecule inhibitor targeting protein arginine methyltransferase 5 in pancreatic and colorectal cancers. <i>Oncotarget</i> , 2017, 8, 39963-39977.	0.8	38
39	Abstract 5783: In vitro modeling of patient derived bladder cancer cell lines in 3D culture systems. , 2017, , .		0
40	Overview of DNA repair pathways, current targets, and clinical trials bench to clinic. , 2016, , 1-54.		6
41	Regulation of HIF1 α under Hypoxia by APE1/Ref-1 Impacts CA9 Expression: Dual Targeting in Patient-Derived 3D Pancreatic Cancer Models. <i>Molecular Cancer Therapeutics</i> , 2016, 15, 2722-2732.	1.9	91
42	Identification and Characterization of New Chemical Entities Targeting Apurinic/Apyrimidinic Endonuclease 1 for the Prevention of Chemotherapy-Induced Peripheral Neuropathy. <i>Journal of Pharmacology and Experimental Therapeutics</i> , 2016, 359, 300-309.	1.3	48
43	Tissue Transglutaminase Activates Cancer-Associated Fibroblasts and Contributes to Gemcitabine Resistance in Pancreatic Cancer. <i>Neoplasia</i> , 2016, 18, 689-698.	2.3	27
44	Applying Small Molecule Signal Transducer and Activator of Transcription-3 (STAT3) Protein Inhibitors as Pancreatic Cancer Therapeutics. <i>Molecular Cancer Therapeutics</i> , 2016, 15, 794-805.	1.9	35
45	STAT3 in the systemic inflammation of cancer cachexia. <i>Seminars in Cell and Developmental Biology</i> , 2016, 54, 28-41.	2.3	171
46	Abstract 613: Astrocytes and endothelial colony forming cells (ECFCs) influence the migration and drug response of glioblastoma cells in a 3D culture model. , 2016, , .		0
47	Abstract 1246: Development of STAT3 dual-targeting strategies for the treatment of pancreatic cancer. , 2016, , .		0
48	Abstract 4740: Targeting Ref-1/APE1 pathway inhibition in pancreatic cancer using APX3330 for clinical trials. , 2016, , .		0
49	Abstract 5183: Efficacy study of APX3330, a Ref-1 redox inhibitor, and Gemcitabine in a mouse pancreatic ductal adenocarcinoma model. , 2016, , .		0
50	Abstract B51: Regulation of HIF1 α under hypoxia by APE1/Ref-1 impacts CA9 expression: Dual-targeting in patient-derived 3D pancreatic cancer models. , 2016, , .		1
51	Longitudinal Bioluminescence Imaging of Primary Versus Abdominal Metastatic Tumor Growth in Orthotopic Pancreatic Tumor Models in NSG Mice. <i>Pancreas</i> , 2015, 44, 64-75.	0.5	9
52	Apurinic/Apyrimidinic Endonuclease/Redox Factor-1 (APE1/Ref-1) Redox Function Negatively Regulates NRF2. <i>Journal of Biological Chemistry</i> , 2015, 290, 3057-3068.	1.6	57
53	Abstract B158: Targeting APE1/Ref-1 results in inhibition of hypoxia signaling genes. , 2015, , .		3
54	Abstract B19: Redox factor 1 (Ref-1) signaling in the interaction between pancreatic tumor cells and cancer-associated fibroblasts. , 2015, , .		0

#	ARTICLE	IF	CITATIONS
55	Targeting DNA repair pathways for cancer treatment: what's new?. <i>Future Oncology</i> , 2014, 10, 1215-1237.	1.1	159
56	Development of Selective Inhibitors for Human Aldehyde Dehydrogenase 3A1 (ALDH3A1) for the Enhancement of Cyclophosphamide Cytotoxicity. <i>ChemBioChem</i> , 2014, 15, 701-712.	1.3	51
57	Selective ALDH3A1 Inhibition by Benzimidazole Analogues Increase Mafosfamide Sensitivity in Cancer Cells. <i>Journal of Medicinal Chemistry</i> , 2014, 57, 449-461.	2.9	60
58	Abstract 4961: Longitudinal bioluminescence imaging of primary versus abdominal metastatic tumor growth in orthotopic pancreatic tumor models in NOD/SCID ^{3(-/-)} mice. , 2014, , .		0
59	991 APE1/REF-1 REGULATES SURVIVIN-MEDIATED DRUG RESISTANCE IN PROSTATE CANCER CELLS. <i>Journal of Urology</i> , 2013, 189, .	0.2	0
60	Blockade of Base Excision Repair. , 2012, , 29-53.		5
61	APE1/Ref-1 Role in Redox Signaling: Translational Applications of Targeting the Redox Function of the DNA Repair/Redox Protein APE1/Ref-1. <i>Current Molecular Pharmacology</i> , 2012, 5, 36-53.	0.7	138
62	APE1/Ref-1 Regulates STAT3 Transcriptional Activity and APE1/Ref-1 "STAT3 Dual-Targeting Effectively Inhibits Pancreatic Cancer Cell Survival. <i>PLoS ONE</i> , 2012, 7, e47462.	1.1	84
63	Impact of APE1/Ref-1 Redox Inhibition on Pancreatic Tumor Growth. <i>Molecular Cancer Therapeutics</i> , 2011, 10, 1698-1708.	1.9	92
64	Inhibition of the redox function of APE1/Ref-1 in myeloid leukemia cell lines results in a hypersensitive response to retinoic acid-induced differentiation and apoptosis. <i>Experimental Hematology</i> , 2010, 38, 1178-1188.	0.2	39
65	Novel Small-Molecule Inhibitor of Apurinic/Apyrimidinic Endonuclease 1 Blocks Proliferation and Reduces Viability of Glioblastoma Cells. <i>Journal of Pharmacology and Experimental Therapeutics</i> , 2010, 334, 988-998.	1.3	92
66	Reduced Expression of DNA Repair and Redox Signaling Protein APE1/Ref-1 Impairs Human Pancreatic Cancer Cell Survival, Proliferation, and Cell Cycle Progression. <i>Cancer Investigation</i> , 2010, 28, 885-895.	0.6	50
67	DNA Repair and Redox Signaling. , 2010, , 133-168.		3
68	Abstract 1963: Novel small molecule inhibitor of the endonuclease function of the APE1 DNA repair and redox signaling enzyme blocks proliferation and reduces viability of glioblastoma cells. , 2010, , .		0
69	Small-molecule inhibitors of proteins involved in base excision repair potentiate the anti-tumorigenic effect of existing chemotherapeutics and irradiation. <i>Future Oncology</i> , 2009, 5, 713-726.	1.1	36
70	Role of APE1 in differentiated neuroblastoma SH-SY5Y cells in response to oxidative stress: Use of APE1 small molecule inhibitors to delineate APE1 functions. <i>DNA Repair</i> , 2009, 8, 1273-1282.	1.3	56
71	Embryonic stem cells lacking the epigenetic regulator Cfp1 are hypersensitive to DNA-damaging agents and exhibit decreased Ape1/Ref-1 protein expression and endonuclease activity. <i>DNA Repair</i> , 2009, 8, 1411-1423.	1.3	4
72	Going Ape as an Approach to Cancer Therapeutics. <i>Antioxidants and Redox Signaling</i> , 2009, 11, 651-667.	2.5	100

#	ARTICLE	IF	CITATIONS
73	Knockdown of the DNA repair and redox signaling protein Ape1/Ref-1 blocks ovarian cancer cell and tumor growth. <i>DNA Repair</i> , 2008, 7, 177-186.	1.3	85
74	Role of the Multifunctional DNA Repair and Redox Signaling Protein Ape1/Ref-1 in Cancer and Endothelial Cells: Small-Molecule Inhibition of the Redox Function of Ape1. <i>Antioxidants and Redox Signaling</i> , 2008, 10, 1853-1867.	2.5	145
75	Enhancement of Cisplatin [<i>cis</i> -Diammine Dichloroplatinum (II)] Cytotoxicity by <i>O</i> ⁶ -Benzylguanine Involves Endoplasmic Reticulum Stress. <i>Journal of Pharmacology and Experimental Therapeutics</i> , 2008, 327, 442-452.	1.3	38
76	DNA Repair Proteins as Molecular Targets for Cancer Therapeutics. <i>Anti-Cancer Agents in Medicinal Chemistry</i> , 2008, 8, 417-425.	0.9	94
77	Manipulation of Base Excision Repair to Sensitize Ovarian Cancer Cells to Alkylating Agent Temozolomide. <i>Clinical Cancer Research</i> , 2007, 13, 260-267.	3.2	125
78	The DNA base excision repair protein Ape1/Ref-1 as a therapeutic and chemopreventive target. <i>Molecular Aspects of Medicine</i> , 2007, 28, 375-395.	2.7	244
79	DNA repair in neurons: So if they don't divide what's to repair?. <i>Mutation Research - Fundamental and Molecular Mechanisms of Mutagenesis</i> , 2007, 614, 24-36.	0.4	216
80	Potential of Melphalan-Induced Cytotoxicity through Targeting of the Base Excision Repair Pathway in Multiple Myeloma. <i>Blood</i> , 2007, 110, 4799-4799.	0.6	0
81	Role of GADD34 in modulation of cisplatin cytotoxicity. <i>Biochemical Pharmacology</i> , 2006, 71, 239-247.	2.0	12
82	Role of glutathione and nucleotide excision repair in modulation of cisplatin activity with <i>O</i> ⁶ -benzylguanine. <i>Cancer Chemotherapy and Pharmacology</i> , 2005, 55, 333-342.	1.1	16
83	Effect of Cell Cycle Inhibition on Cisplatin-Induced Cytotoxicity. <i>Journal of Pharmacology and Experimental Therapeutics</i> , 2005, 312, 206-213.	1.3	21
84	Imbalancing the DNA base excision repair pathway in the mitochondria; targeting and overexpressing N-methylpurine DNA glycosylase in mitochondria leads to enhanced cell killing. <i>Cancer Research</i> , 2003, 63, 608-15.	0.4	64
85	Enhancement of platinum-induced cytotoxicity by <i>O</i> ⁶ -benzylguanine. <i>Molecular Cancer Therapeutics</i> , 2003, 2, 633-40.	1.9	26
86	Implication of p53 in base excision DNA repair: in vivo evidence. <i>Oncogene</i> , 2002, 21, 731-737.	2.6	106